Hep B drug pipepline and dates

[Airquake]

Hepatitis B therapy pipeline
Project
Company
Pharmacology
Trial ID
Data due?
Phase II
GS-9620
Gilead Sciences
TLR7 agonist
NCT02166047 & NCT02579382
Imminent & Dec 2016
GS-4774
Gilead Sciences/Globeimmune
Therapeutic vaccine
NCT02174276
Imminent
Myrcludex B
Hepatera
Viral entry inhibitor
NCT02637999
Imminent
REP 2139
Replicor
HBsAg release inhibitor
NCT02726789
Sep 2016
ARC-520
Arrowhead Pharmaceuticals
RNAi therapeutic
NCT02604199 and 4 others
Oct 2016
ARB-1467
Arbutus Biopharma
RNAi therapeutic
NCT02631096
Oct 2016
CMX157
Chimerix/Contravir
NNRTI
NCT02710604
Oct 2016
GC1102
Green Cross (Korea)
Recombinant hep B immunoglobulin
NCT02569372
May 2017
RO6864018
Roche
Not disclosed
NCT02391805
Sep 2017
SB 9200
Spring Bank Pharmaceuticals
RIG-I & NOD2 activator
NCT02751996
Dec 2017
REP 2165
Replicor
HBsAg release inhibitor
NCT02565719
Sep 2018
Phase I
NVR 3-778
Johnson & Johnson
Capsid inhibitor
NCT02401737
Imminent
JNJ-56136379
Johnson & Johnson
Not disclosed
NCT02662712
Nov 2016
IONIS-HBV-LRx
GlaxoSmithKline/Ionis
Hepatitis B antisense
NCT02647281
Nov 2016
HepTcell (FP-02.2)
Altimmune
Therapeutic vaccine
NCT02496897
Feb 2017
RO7020322
Roche
Not disclosed
NCT02604355
Apr 2017
ARC-521
Arrowhead Pharmaceuticals
ccc DNA-targeting RNAi
NCT02797522
Jun 2017
TG1050
Transgene
Therapeutic vaccine
NCT02428400
Mar 2018
INO-1800/RG7944
Inovio Pharmaceuticals
Therapeutic vaccine
NCT02431312
Dec 2018
RG7834
Roche
Not disclosed
–
(1st pt in Q4 2015)
AIC649
Aicuris
Therapeutic vaccine
–
–
EYP001
Enyo Pharma
Farnesoid X receptor agonist
–
–
GSK3228836
GlaxoSmithKline/Ionis
Hepatitis B antisense
–
–
Source: EvaluatePharma and Clinicaltrials.gov.

[Royal36]

not Hbeag-

[Jatashankar]

i feel like some new drug by 2020, lets c.

[Royal36]

It is coming before 2020 but for Hbeag -

[StephenCastlecrag]

Press release from Abivax:

* Post-treatment monitoring of patients will be continued as per protocol in order to provide additional insight on clinical trial outcomes and secondary endpoints

* Future development of ABX203 under review, including addition of an adjuvant, new administration schedules and therapeutic combinations

[StephenCastlecrag]

It is 5.5 log reduction in hbvdna, not HBsAg. Since patients are on Entecavir, these types of reduction in hbvdna are not unusual.

[Royal36]

I feel the only leading HBV drug on pipeline is ARWR( Arc-520).

[Royal36]

Recently, Arrowhead Pharmaceuticals reported that combining ARC-520 and Bristol-Myers Squibb's (NYSE:BMY) Baraclude resulted in up to 5.5 log, or 99.99% reductions in serum HBV DNA. Patients with HBeAg-negative mutation -- a tough-to-treat variation -- achieved reductions that put them below the limit of quantification, too.

Those results boost confidence that ARC-520 combination therapy could provide a functional cure for the 350-million-plus people worldwide who are infected with hepatitis B.

[StephenCastlecrag]

This is a very comprehensive and timely article about HBV drugs in development. ABX203 was not mentioned, even though one clinical trial is still on-going. Most of the others are well-known to us all - very hard to get excited about.
It would be interesting to know more about the "undisclosed mechanism" of the Johnson& Johnson and Roach's drugs. It is hard to tell whether they do not want to disclose because they are just like the others or represent some new approaches.

[Airquake]

Couple months ago they announced that they gave up on ABX203

[Airquake]

Hepatitis B therapy pipeline
Project / Company / Pharmacology / Trial ID / Data due?
Phase II
GS-9620 Giled Sciences TLR7 agonist NCT02166047 & NCT02579382 Imminent & Dec 2016
GS-4774 Sciences/Globeimmune Therapeutic vaccine NCT02174276 Imminent
Myrcludex B Viral entry inhibitor NCT02637999 Imminent
REP 2139 Replicor HBsAg release inhibitor
NCT02726789 Sep 2016
ARC-520 Arrowhead Pharmaceuticals RNAi therapeutic NCT02604199 and 4 others Oct 2016
ARB-1467 Arbutus Biopharma RNAi therapeutic NCT02631096 Oct 2016
CMX157 Chimerix/Contravir NNRTI NCT02710604 Oct 2016
GC1102 Green Cross (Korea) Recombinant hep B immunoglobulin NCT02569372 May 2017
RO6864018 Roche Not disclosed NCT02391805 Sep 2017
SB 9200 Spring Bank Pharmaceuticals RIG-I & NOD2 activator NCT02751996 Dec 2017
REP 2165 Replicor HBsAg release inhibitor NCT02565719 Sep 2018
Phase I
NVR 3-778 Johnson & Johnson Capsid inhibitor NCT02401737 Imminent
JNJ-56136379 Johnson & Johnson Not disclosed NCT02662712 Nov 2016
IONIS-HBV-LRx GlaxoSmithKline/Ionis Hepatitis B antisense NCT02647281 Nov 2016
HepTcell (FP-02.2) Altimmune Therapeutic vaccine NCT02496897 Feb 2017 RO7020322 Roche Not disclosed NCT02604355 Apr 2017
ARC-521 Arrowhead Pharmaceuticals ccc DNA-targeting RNAi NCT02797522 Jun 2017
TG1050 Transgene Therapeutic vaccine NCT02428400 Mar 2018
INO-1800/RG7944 Inovio Pharmaceuticals Therapeutic vaccine NCT02431312 Dec 2018
RG7834 Roche Not disclosed – (1st pt in Q4 2015)
AIC649 Aicuris Therapeutic vaccine – –
EYP001 Enyo Pharma Farnesoid X receptor agonist – –
GSK3228836 GlaxoSmithKline/Ionis Hepatitis B antisense – –
Source: EvaluatePharma and Clinicaltrials.gov.

[Airquake]

http://seekingalpha.com/article/4000028-hepatitis-b-developers-try-repeat-gileads-hep-c-trick

[sorte]

more readable form here :)

http://www.hepb.org/treatment-and-management/drug-watch/

[Airquake]

The problem is that copying the link from this site is problematic

[Airquake]

This one has the dates!